OA
Optic atrophy is a term for damage to the optic nerve that results in progressive loss of retinal ganglion cells (RGCs) and their axons, the nerve fibers that transmit visual signals from the retina to the brain. It is a final common pathway for many eye diseases and can cause severe, irreversible vision loss.
Optic atrophy is classified based on its cause. All types share the same fundamental pathology: death of retinal ganglion cells and loss of retinal nerve fiber layer (RNFL) thickness.
Primary Optic Atrophy (POA)
Results from lesions of the visual pathway between the retina and the lateral geniculate body, without prior optic disc swelling. Causes include hereditary conditions (ADOA, LHON), compressive tumors, and demyelinating diseases.
Glaucomatous Optic Atrophy (GOA)
The most common form globally, resulting from elevated intraocular pressure damaging RGC axons at the optic nerve head. Glaucoma affects approximately 60 million people worldwide.
Secondary Optic Atrophy
Develops following optic disc swelling (papilledema) or other optic nerve insults, including ischemic optic neuropathy, optic neuritis, or trauma. The disc becomes grey or pale with indistinct margins.
Leber Hereditary Optic Neuropathy (LHON)
A mitochondrial genetic disease causing rapid bilateral vision loss in young adults. Raxone (idebenone) is approved in the EU for LHON; LUMEVOQ gene therapy targets a single mitochondrial mutation. Most patients remain undertreated.
Symptoms vary depending on the type and severity of optic atrophy, but commonly include:
The treatment options for optic atrophy are extremely limited. There is no approved neuroprotective therapy for the vast majority of optic atrophy patients.
Lowering IOP slows RGC loss in glaucoma but does not restore already-damaged nerve fibers or protect against apoptosis already in progress.
Limited to LHON patients and only EU-approved. Helps some LHON patients stabilize or partially recover vision, but is not a neuroprotective agent for other forms of optic atrophy.
Addresses a single mitochondrial mutation (m.11778G>A in MT-ND4) responsible for a subset of LHON cases. No relevance to other optic atrophy types.
The critical gap
For patients with primary optic atrophy, secondary optic atrophy, glaucomatous optic atrophy, or non-ND4 LHON, there is no approved neuroprotective treatment. The market is valued at $2.53 billion and projected to reach $5.87 billion by 2034, driven by unmet need.
The most striking preclinical evidence for SBC003 comes from a study in rhesus monkeys with naturally occurring, spontaneous unilateral optic atrophy, a highly translational model.
Rhesus Monkey Study (Aging Cell, 2022)
Design
2 male rhesus monkeys with spontaneous unilateral optic atrophy
Treatment
Oral SBC003, escalating doses: 5→15→30→50 mg/kg/day over ~13 weeks
RNFL outcome
Significant RNFL thickness increase in both diseased eyes (p<0.05 and p<0.005)
Internal controls
No change in healthy contralateral eyes, confirming disease-specific effect
These results are significant because: (1) the monkeys had naturally occurring disease, not artificially induced, making them a more realistic model; (2) RNFL thickening suggests actual nerve fiber restoration, not just slowing of loss; (3) the healthy contralateral eyes served as perfect internal controls, confirming no off-target effects.
SBC003 is in early research stage for optic atrophy. It has not been approved for this indication and is not available to patients outside of authorized research settings.
Glaucoma Research Foundation
Research, education, and support for glaucoma patients
Leber's Hereditary Optic Neuropathy Society
Patient community and resources for LHON
ClinicalTrials.gov: Optic Atrophy
Search for open optic atrophy clinical trials
American Glaucoma Society
Professional society; find a glaucoma specialist
Pioneering first-in-class orally bioavailable lipid therapeutics to halt neurodegeneration and restore vision. Clinical-stage. Basel, Switzerland.
© 2026 SunRegen Healthcare AG. All rights reserved.
Business Parc Reinach, Christoph Merian-Ring 11, 4153 Reinach, Switzerland
UID: CHE-295.245.274
This website contains forward-looking statements regarding future products, development plans, and business strategies. Actual results may differ materially. Nothing on this site constitutes medical or investment advice.